Company Encyclopedia
View More
name
SINOPHARM TECH
08156.HK
Sinopharm Tech Holdings Limited, an investment holding company, engages in trading of medical and related products in China. It is involved in the provision of Internet plus solution services, including provision of internet related solution services; and manufacturing and distribution of personal protective equipment, consumables, and other related goods. The company also engages in providing supply chain services, including provision of supply chain management, data analysis, and related services; and trading of related goods, and trading of medial and related products. Sinopharm Tech Holdings Limited was formerly known as China Vanguard You Champion Holdings Limited and changed its name to Sinopharm Tech Holdings Limited in June 2019.
180.82 B
08156.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking14/21
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE0.49%D
    • Profit Margin-1.42%D
    • Gross Margin23.23%D
  • Growth ScoreA
    • Revenue YoY48.39%A
    • Net Profit YoY95.60%A
    • Total Assets YoY16.29%A
    • Net Assets YoY82.15%A
  • Cash ScoreC
    • Cash Flow Margin-7064.94%E
    • OCF YoY48.39%A
  • Operating ScoreA
    • Turnover1.27A
  • Debt ScoreE
    • Gearing Ratio170.93%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sinopharm Tech Holdings Ltd. Announces Date for Annual General Meeting

    Sinopharm Tech Holdings Ltd. will hold its annual general meeting on December 19, 2025, in Hong Kong. The meeting will discuss ordinary resolutions, including a share repurchase limit of up to 10% of shares in issue. This announcement was originally published by Sinopharm Tech Holdings Ltd. via the Hong Kong Stock Exchange's Issuer Information Service.

    Reuters·
    HK
    08156
    +1.56%
    Reuters·
    HK
    08156
    +1.56%

    SINOPHARM TECH: Guo Zuyi appointed as the company secretary

    According to the Zhitong Finance APP, SINOPHARM TECH announced that Ms. Huang Ziling has resigned as the company secretary, effective from October 23, 2025. Mr. Guo Zuyi has been appointed as the company secretary, effective from October 23, 2025

    Zhitong·
    HK
    08156
    +1.56%
    Zhitong·
    HK
    08156
    +1.56%

    Sinopharm Tech Holdings Ltd. Publishes 2025 Annual Report

    Sinopharm Tech Holdings Ltd. has published its Annual Report for the year ending June 30, 2025. The report emphasizes the company's strategic focus on the healthcare and pharmaceutical supply chain sectors, highlighting its commitment to business development and operational stability. The management discussion provides insights into the company's activities and developments during the year. The full report is accessible via a provided link.

    Reuters·
    HK
    08156
    +1.56%
    Reuters·
    HK
    08156
    +1.56%

    SINOPHARM TECH announced its annual performance, with a loss attributable to shareholders of approximately HKD 900,000, a significant decrease of about 95% year-on-year

    SINOPHARM TECH announced its annual performance for the period ending June 30, 2025, with revenue of approximately HKD 61.3 million, an increase of about 48% year-on-year. The loss attributable to shareholders was approximately HKD 900,000, a significant decrease of about 95% year-on-year. The loss per share was HKD 0.19. The revenue growth was mainly due to increased demand in the health products market and improved supply chain service efficiency. The board pointed out that the reasons for the improvement in financial performance include growth in gross profit, cost control, and reduced financing costs

    Zhitong·
    HK
    08156
    +1.56%
    Zhitong·
    HK
    08156
    +1.56%

    SINOPHARM TECH issued a profit warning, expecting the annual loss attributable to shareholders to not exceed HKD 1 million, a significant decrease of approximately 95% year-on-year

    SINOPHARM TECH expects that the annual loss attributable to the company's owners for the year ending June 30, 2025, will not exceed HKD 1 million, a significant decrease of approximately 95% year-on-year. The main factors contributing to the improvement in financial performance include a business improvement leading to an increase in gross profit of approximately HKD 9.2 million, strengthened cost control, capitalized loan income of approximately HKD 3.9 million, and reduced financing costs

    Zhitong·
    HK
    08156
    +1.56%
    Zhitong·
    HK
    08156
    +1.56%
    © 2025 Longbridge｜Disclaimer